[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354561-105":59,"doc-detail-354561-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","the-promising-cancer-treatment-approach-in-cancer-immunotherapy-dendritic-cell-based-vaccines","The promising cancer treatment approach in cancer immunotherapy - dendritic cell-based vaccines","","Dendritic cells (DCs) function as highly professional antigen-presenting cells capable of initiating and modulating adaptive immune responses, making DC-based vaccines a promising strategy for tumor immunotherapy. This review details DC biological properties, summarizes major DC vaccine platforms, and analyzes three representative approaches: tumor-lysate–loaded DC vaccines, personalized neoantigen-pulsed DC vaccines, and DC-derived exosome vaccines. It also reviews clinical trial outcomes from the past five years, highlights translational challenges in limited clinical application, and outlines emerging combination regimens with chemotherapy, radiotherapy, or immune checkpoint blockade.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-promising-cancer-treatment-approach-in-cancer-immunotherapy-dendritic-cell-based-vaccines/354561/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-promising-cancer-treatment-approach-in-cancer-immunotherapy-dendritic-cell-based-vaccines/354561.png","ImageObject",300,407,{"name":92,"@type":93},"kopisore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What is the main therapeutic rationale for dendritic cell (DC) vaccines in cancer immunotherapy?","Question",{"text":113,"@type":114},"DCs are highly professional antigen-presenting cells that can initiate and modulate adaptive immune responses. They support efficient antigen presentation and prime antigen-specific T-cell activation, enabling antitumor immunity.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"Which three representative DC vaccine strategies are reviewed?",{"text":118,"@type":114},"The review analyzes (i) DC vaccines loaded with tumor lysates, (ii) personalized neoantigen-pulsed DC vaccines, and (iii) DC-derived exosome vaccines.",{"name":120,"@type":111,"acceptedAnswer":121},"What factors limit broad clinical application of DC vaccines despite encouraging results?",{"text":122,"@type":114},"Key challenges include functional heterogeneity of dendritic cells and immunosuppressive tumor microenvironments, which need to be overcome for wider use.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},354561,1790453702,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","TYPE Review  \nPUBLISHED 24 July 2026  \nDOI 10.3389/fimmu.2026.1902454  \nOPEN ACCESS  \nEDITED BY  \nBrian J. Czerniecki,  \nMofﬁtt Cancer Center, United States  \nREVIEWED BY  \nTan-Huy Chu,  \nTam Anh Research Institute, Vietnam Tikhon Redkin,  \nSirius University, Russia  \n*CORRESPONDENCE  \nZhiyao He  \n [heyaode@163.com](heyaode@163.com);  \n [zhiyaohe@scu.edu.cn](zhiyaohe@scu.edu.cn)[ ](zhiyaohe@scu.edu.cn)†These authors have contributed equally to this work  \nRECEIVED 07 June 2026  \nREVISED 06 July 2026  \nACCEPTED 13 July 2026  \nPUBLISHED 24 July 2026  \nCITATION  \nWang J, Jia X, Zhang Y,  \nWang X, Fu Y and He Z (2026)  \nThe promising cancer treatment  \napproach in cancer immunotherapy: dendritic cell-based vaccines.  \nFront. Immunol. 17:1902454 .  \ndoi: 10.3389/fimmu.2026.1902454  \nCOPYRIGHT  \n© 2026 Wang, Jia, Zhang, Wang, Fu and He. This is an open-access article distributed under the terms of the  \nCreative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe promising cancer treatment approach in cancer immunotherapy:  \ndendritic cell-based vaccines  \nJingwen Wang 1†, Xibiao Jia 2†, Yaxin Zhang 1, Xiaoyu Wang 1, Yunhai Fu 1 and Zhiyao He 1,3*  \n1 Department of Pharmacy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, China, 2 Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China, 3 Key Laboratory of Drug-Targeting and Drug Delivery System of the Education Ministry and Sichuan Province, Sichuan Engineering Laboratory for Plant-Sourced Drug and Sichuan Research Center for Drug Precision Industrial Technology, West China School of Pharmacy, Sichuan University, Chengdu, China  \nDendritic cells (DCs), as the most protent professional antigen-presenting cells (APCs), possess an exceptional capacity to initiate and modulate adaptive immune responses, rendering DC-based vaccines a highly promising approach in tumor immunotherapy. This review explores the biological properties of DCs, establishing a foundation for the rational development of DC vaccine. We further provide a comprehensive overview of current mainstream DC vaccine platforms, with analysis of three representative strategies: (i) DC vaccines loaded with tumor lysates; (ii) personalized neoantigen-pulsed DC vaccines; and (iii) DC-derived exosome vaccines, a rapidly emerging cell-free therapeutic modality. With respect to clinical translation, we summarize the outcomes of clinical trials conducted over the past ﬁve years, particularly targeting high-mortality malignancies. While the results are encouraging, the broad clinical application remains limited, posing several challenges, including functional heterogeneity of DCs and immunosuppressive tumor microenvironment, which need to be overcome. Combination strategies, such as DC vaccination paired with chemotherapy, radiotherapy or immune checkpoint blockade, are increasingly recognized as essential for enhancing therapeutic efﬁcacy. With the sustainable progress in tumor immunobiology and advanced bioengineering in the future, the development of DC vaccines will be accelerated, offering novel therapeutic prospects for patients with refractory cancers.  \nKEYWORDS  \ncancer, cancer vaccines, DC vaccines, dendritic cells, immunotherapy  \n1 Introduction  \nIn the United States, cancer is the second-leading cause of death overall. According to the latest cancer statistics report, approximately 2,114,850 new cases and 626,140 cancer deaths are projected in 2026 (1) . When zooming out to the worldwide public health landscape, a sta","cbCaiqF8lCpcviO2","https://ap.wps.com/l/cbCaiqF8lCpcviO2","pdf",3541032,14,"English","# Abstract\n## Introduction\n## DC biological properties and rationale for DC vaccines\n## Major DC vaccine platforms\n## Representative strategies\n## Clinical translation and trial outcomes","[{\"question\":\"What is the main therapeutic rationale for dendritic cell (DC) vaccines in cancer immunotherapy?\",\"answer\":\"DCs are highly professional antigen-presenting cells that can initiate and modulate adaptive immune responses. They support efficient antigen presentation and prime antigen-specific T-cell activation, enabling antitumor immunity.\"},{\"question\":\"Which three representative DC vaccine strategies are reviewed?\",\"answer\":\"The review analyzes (i) DC vaccines loaded with tumor lysates, (ii) personalized neoantigen-pulsed DC vaccines, and (iii) DC-derived exosome vaccines.\"},{\"question\":\"What factors limit broad clinical application of DC vaccines despite encouraging results?\",\"answer\":\"Key challenges include functional heterogeneity of dendritic cells and immunosuppressive tumor microenvironments, which need to be overcome for wider use.\"}]","The promising cancer treatment approach in cancer immunotherapy - dendritic cell-based vaccines | PDF",1790111970,35,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/16f5c09f92cb7bb79cd3d882a8236333.webp",983,1389,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e13e2848584d84cf9414a281c082610.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0b024ffc337b3096f1596af2aaa0b91e.webp",981,1386,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5a009786cb387c3f3a4dcc18c3507436.webp",980,1385]